Investor Relations | Aspen Pharmacare (2024)

Investor Hub

We are a global specialty and branded pharmaceutical company, improving the health of patients across the world through our high quality, affordable medicines. Active at every stage of the value chain, we are uniquely diversified by geography, product and manufacturing capability.

Download Fact Sheet

Group Chief Executive Strategy
Investment Case
Analyst Coverage

Stephen Saad

Group Chief Executive

Our business strategy is to create value for our stakeholders by promoting access to medicines through building robust product portfolios that achieve organic growth and by leveraging our world-class manufacturing capacities and capabilities. We seek to achieve this by building a differentiated portfolio of relevant IP, creating value through our complex manufacturing capabilities and enabling access through our globally integrated supply chain.

Our market positioning is focused on opportunities presented by emerging markets, balanced with presence in more established, stable developed markets. Through our dynamic portfolio management model, we build, optimise and reshape our basket of products to achieve a global product portfolio of niche, specialty products complemented by leading regional brands, aligned to our manufacturing capability.

We have proven manufacturing capability and capacity, creating access and sustainability collaboration opportunities for multinationals.

CEO's Report

Download

	Firm	Analyst	Contact Details
Covering analyst	HSBC	Raj Sinha	raj.sinha@hsbc.com
Covering analyst	Investec	Letlotlo Lenake	letlotlo.lenake@investec.co.za
Covering Analyst	JPM	Alex Comer	alex.r.comer@jpmorgan.com
Covering analyst	Nedbank	Luyanda Njilo	luyandan@nedbank.co.za
Covering Analyst	RMBMS	Roy Campbell	roy.campbell@rmbmorganstanley.com
Covering analyst	Standard Bank	Anuja Joshi	anujajoshi@sbgsecuritiescom

Latest Results: H1 2024

Revenue increased by 10%
(2% CER) to

R0,1 billion

December 2022: R19,2 billion

Normalised EBITDA increased by 2% (-5% CER) to

R0,2 billion

December 2022: R5,1 billion

Normalised headline earnings per share increased by 1% (-5% in CER) to

60 cents

December 2022: 679,6 cents

Operating cash flow per share increased by 44% to

50 cents

December 2022: 384,3 cents

Dividend declared to shareholders increased by 5% to

0 cents per ordinary share

June 2022: 326 cents

Financial Results and Presentations

FY2024
FY2023
FY2022
FY2021
ARCHIVE

Interim Results

Fact Sheet

1 file(s) 224.40 KB

Download

Illustrative Revenue Disclosure

1 file(s) 239.25 KB

Download

Interim Results Short Form Announcement

1 file(s) 451 KB

Download

Interim Results Booklet

1 file(s) 152.14 KB

Download

Interim Results Presentation

1 file(s) 2.72 MB

Download

Interim Results Presentation Webcast

1 file(s) 0.00 KB

View

Results booklet – Excel downloads

1 file(s) 118.50 KB

Download

Additional Presentations and webcasts

Aspen 2023 Capital Markets Day – NDB, France

1 file(s) 11.78 MB

Download

Capital Markets Day Webcast

1 file(s) 0.00 KB

Download

Annual Results

Annual Financial Statements

1 file(s) 5.61 MB

Download

Annual Results Booklet

1 file(s) 515.16 KB

Download

Annual Results Presentation

1 file(s) 909.31 KB

Download

Annual Results Short Form Announcement

1 file(s) 451 KB

Download

Fact Sheet

1 file(s) 224.40 KB

Download

Illustrative Revenue Disclosure

1 file(s) 239.25 KB

Download

Annual Results Presentation Webcast

1 file(s) 28.00 KB

View Online